Sex Hormone Binding Globulin (SHBG)
Dec 26, 2025
Sex Hormone Binding Globulin (SHBG) Blood Test
What It Is, Why It Matters, and How to Interpret Your Results
Sex hormone binding globulin plays a central role in regulating how much testosterone and estrogen are available to tissues. When interpreted in context, SHBG helps explain why total hormone levels alone often fail to reflect true biological activity.
Quick Take
Sex hormone binding globulin, commonly called SHBG, is a protein that binds testosterone and estradiol in the bloodstream and regulates how much hormone is biologically available. SHBG does not change how much hormone is produced, but it strongly influences how testosterone and estrogen are distributed and accessed by tissues.
Differences in SHBG explain why individuals with similar total hormone levels can experience very different physiological effects. SHBG is essential for accurate interpretation of total and free testosterone and, in women, estradiol balance as well.
Why Strive for Optimal SHBG?
SHBG reflects how efficiently the body regulates hormone availability.
When SHBG levels are balanced, testosterone and estrogen distribution aligns more closely with physiological needs. This supports stable signaling across tissues involved in muscle maintenance, energy regulation, mood, reproductive health, and metabolic function.
Very high or very low SHBG values can signal broader metabolic or hormonal imbalance. Optimizing SHBG is not about targeting a specific number, but about supporting the metabolic and endocrine conditions that allow appropriate hormone distribution over time.
In women in particular, SHBG often reflects both reproductive and metabolic health. Because estrogen increases SHBG production and insulin resistance lowers it, SHBG becomes a useful integrative marker across the menstrual cycle, perimenopause, and menopause.
What Does Optimal SHBG Mean?
There is no single SHBG value that defines optimal health.
Higher SHBG levels indicate that a larger proportion of testosterone and estradiol is tightly bound and unavailable to tissues. In women, very high SHBG can lead to low free testosterone even when total testosterone appears normal. This is commonly seen with oral estrogen therapy or hyperthyroidism.
Lower SHBG levels indicate less binding capacity and relatively higher free testosterone. In women, low SHBG is strongly associated with insulin resistance and polycystic ovary syndrome. Even mildly elevated total testosterone can translate into disproportionately high free testosterone when SHBG is low.
Interpretation depends on how SHBG interacts with total testosterone, calculated free testosterone, estradiol status, symptoms, metabolic health, and longitudinal trends rather than a single value.
Why Tracking SHBG Over Time Matters
SHBG changes more gradually than testosterone, often over months rather than days.
Tracking SHBG over time helps distinguish persistent metabolic or hormonal shifts from short term fluctuations in testosterone or estradiol levels. Stable or improving SHBG trends often reflect changes in insulin sensitivity, thyroid signaling, liver health, or overall metabolic balance.
In women, trends can reflect cycle variability, transition into perimenopause, initiation of hormone therapy, or shifts in metabolic health. Because SHBG responds to both estrogen exposure and insulin signaling, it can act as a bridge between reproductive and metabolic physiology.
When tracked alongside total and free testosterone, SHBG trends provide insight into whether changes in hormone availability are driven by distribution rather than production.
What Is Sex Hormone Binding Globulin?
Sex hormone binding globulin is a protein produced primarily by the liver. It binds circulating sex hormones, including testosterone and estradiol, and regulates their access to tissues.
Hormones bound tightly to SHBG are not readily available to interact with cells. Only unbound hormone and the fraction loosely bound to albumin are considered biologically available. SHBG therefore functions as a gatekeeper that controls hormone access rather than hormone synthesis.
Why SHBG Matters
Determines hormone availability rather than production
SHBG does not increase or decrease testosterone or estrogen production. It determines how much circulating hormone is available to tissues. Higher SHBG lowers free hormone levels, while lower SHBG increases them.
Explains discordant hormone results
Two individuals can have the same total testosterone but very different free testosterone levels due to differences in SHBG. In women, this is a common reason laboratory values and symptoms do not align, particularly in PCOS or during perimenopause.
Sensitive to metabolic and hormonal signals
SHBG responds to liver function, thyroid signaling, insulin sensitivity, estrogen exposure, and inflammatory state. Changes in SHBG often reflect broader metabolic or endocrine patterns rather than isolated reproductive issues.
Who Should Pay Extra Attention to SHBG?
SHBG deserves particular attention in:
Women with symptoms of androgen excess but only mild total testosterone elevation
Women with polycystic ovary syndrome or suspected insulin resistance
Women transitioning through perimenopause
Women on oral estrogen therapy
Postmenopausal women evaluating cardiometabolic health
Individuals whose symptoms do not match total testosterone results
Those using testosterone therapy with fluctuating testosterone levels
How SHBG Is Measured
SHBG is measured directly from a blood sample using standardized immunoassays.
SHBG levels change more slowly than testosterone and are less sensitive to short term variation from sleep or daily activity. Because SHBG is produced by the liver, sustained changes often reflect longer term physiological patterns rather than acute stressors.
What SHBG Levels Mean
Higher SHBG values indicate increased binding of testosterone and estradiol and reduced availability to tissues. In women, elevated SHBG may be seen with oral estrogen therapy, hyperthyroidism, or lower body weight.
Lower SHBG values indicate reduced binding capacity and relatively higher free testosterone. In women, low SHBG commonly appears alongside insulin resistance, elevated triglycerides, and metabolic stress. It is a frequent feature of PCOS and is independently associated with increased risk of type 2 diabetes.
Understanding whether SHBG levels are stable, rising, or falling over time is essential for meaningful interpretation.
Factors That Influence SHBG
Metabolic health
Insulin resistance and increased adiposity are commonly associated with lower SHBG levels. This relationship is particularly relevant in women with PCOS or metabolic syndrome.
Liver function
Because SHBG is produced in the liver, liver health directly influences circulating levels.
Thyroid signaling
Changes in thyroid hormone signaling can increase or decrease SHBG production.
Sex hormones
Testosterone therapy, estrogen exposure, menstrual cycle phase, pregnancy, and hormone replacement therapy can alter SHBG levels over time. Oral estrogen has a stronger effect on SHBG production than transdermal formulations.
Age and genetics
Baseline SHBG varies between individuals and tends to increase gradually with age, although metabolic health significantly modifies this pattern.
How SHBG Fits With Other Rythm Biomarkers
SHBG is central to interpreting total testosterone and calculated free testosterone. Elevated SHBG can explain low free testosterone despite normal total testosterone, while low SHBG can explain higher free testosterone at lower total levels.
In women, SHBG also provides context for estradiol therapy and metabolic markers. Low SHBG often appears alongside elevated triglycerides and unfavorable lipid patterns. Thyroid markers such as TSH and T3 provide additional context when SHBG shifts unexpectedly.
SHBG Versus Testosterone Measures
Total testosterone reflects how much hormone is circulating.
SHBG determines how much of that hormone is bound.
Free testosterone estimates how much hormone is available to tissues.
All three markers are needed to understand androgen status accurately, especially in women where small shifts in binding can meaningfully change free hormone availability.
Frequently Asked Questions
Can SHBG change over time?
Yes. SHBG can change over months in response to metabolic health, thyroid signaling, hormonal therapy, weight change, and reproductive transitions.
Does low SHBG always mean stronger testosterone effects?
Not necessarily. While low SHBG increases free testosterone, it is often associated with metabolic dysfunction that can blunt tissue level hormone response.
Does SHBG affect estrogen in women?
Yes. SHBG binds estradiol as well as testosterone. Changes in SHBG can influence the balance between bound and free estrogen, particularly in women on hormone therapy.
Should SHBG be interpreted alone?
No. SHBG is most informative when interpreted alongside total and free testosterone, estradiol status, and broader metabolic context.
Conclusion
Sex hormone binding globulin plays a critical role in regulating testosterone and estrogen availability. By controlling how much hormone is bound versus free, SHBG explains why total hormone levels alone are often insufficient for understanding androgen and estrogen balance.
When interpreted alongside total testosterone, calculated free testosterone, estradiol, thyroid markers, and metabolic biomarkers, SHBG provides essential clarity into hormone distribution, tissue level signaling, and overall endocrine health over time.
References
European Federation of Clinical Chemistry and Laboratory Medicine (EFLM). Biological Variation Database.
Hammond GL. Diverse roles for sex hormone binding globulin in reproduction. Biology of Reproduction. 2011;85(3):431 to 441.
Goldman AL, et al. Sex hormone binding globulin and risk of type 2 diabetes mellitus. New England Journal of Medicine. 2009;361(12):1152 to 1163.
Selva DM, Hammond GL. Thyroid hormones act indirectly to increase sex hormone binding globulin production. Endocrinology. 2009;150(4):1609 to 1617.
Rosner W, et al. Utility, limitations, and pitfalls in measuring testosterone. An Endocrine Society position statement. Journal of Clinical Endocrinology and Metabolism. 2007;92(2):405 to 413.